Why the study?
Does intravenous DDAVP improve platelet adherence and bleeding time in normal individuals and patients with von Willebrand's disease?
Population
17 individuals, including 5 normal individuals and 12 patients with von Willebrand's disease
Comparison
Intravenous 1-deaminovasopressin vs Baseline (before DDAVP infusion)
Design
Cohort
Follow-up
90 minutes
Authors
Loading...
DDAVP effects differ by vWD subtype; supports subtype-specific testing but leaves open randomized outcome trials.
Does intravenous DDAVP improve platelet adherence and bleeding time in normal individuals and patients with von Willebrand's disease?
DDAVP improves primary hemostasis by enhancing FVIII-vWF-mediated platelet adherence in normal individuals and vWD subtype I, but has little to no effect on bleeding time in subtypes IIa and IIb.
Sakariassen et al. (1984) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: